Skip to content
10-Q

Quarterly Report

PACIRA BIOSCIENCES, INC. PCRX

0001396814-25-000061

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 7, 2025 46.3M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $210.02M
Short Term Investments Q1 2025 · Dec 31, 2024 $207.84M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $283.61M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $276.77M
Current Liabilities Q1 2025 · Mar 31, 2025 $314.73M
Current Liabilities Q1 2025 · Dec 31, 2024 $309.92M
Total Liabilities Q1 2025 · Mar 31, 2025 $788.13M
Total Liabilities Q1 2025 · Dec 31, 2024 $775.17M
Current Assets Q1 2025 · Mar 31, 2025 $759.96M
Current Assets Q1 2025 · Dec 31, 2024 $745.13M
Total Assets Q1 2025 · Mar 31, 2025 $1.59B
Total Assets Q1 2025 · Dec 31, 2024 $1.55B
Shares Diluted Q1 2025 · Mar 31, 2024 52.19M sh
Capex Q1 2025 · Mar 31, 2024 $2.84M
Operating Cash Flow Q1 2025 · Mar 31, 2024 $49.1M
Stockholders Equity Q1 2025 · Mar 31, 2024 $892.16M
Stockholders Equity Q1 2025 · Dec 31, 2023 $870.13M
Eps Diluted Q1 2025 · Mar 31, 2024 $0.19
Eps Basic Q1 2025 · Mar 31, 2024 $0.19
Sga Expense Q1 2025 · Mar 31, 2024 $72.03M
Rd Expense Q1 2025 · Mar 31, 2024 $18.24M
Net Income Q1 2025 · Mar 31, 2024 $8.98M
Operating Income Q1 2025 · Mar 31, 2024 $13.21M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $47.42M
Revenue Q1 2025 · Mar 31, 2024 $167.12M